128 related articles for article (PubMed ID: 9068760)
1. Low dose UVA1 phototherapy in disabling pansclerotic morphoea of childhood.
Gruss C; Stücker M; Kobyletzki G; Schreiber D; Altmeyer P; Kerscher M
Br J Dermatol; 1997 Feb; 136(2):293-4. PubMed ID: 9068760
[No Abstract] [Full Text] [Related]
2. A randomized controlled study of low-dose UVA1, medium-dose UVA1, and narrowband UVB phototherapy in the treatment of localized scleroderma.
Kreuter A; Hyun J; Stücker M; Sommer A; Altmeyer P; Gambichler T
J Am Acad Dermatol; 2006 Mar; 54(3):440-7. PubMed ID: 16488295
[TBL] [Abstract][Full Text] [Related]
3. [Severe course of a mutilating pansclerotic circumscribed scleroderma in childhood. Clinical aspects and therapy].
Stücker M; Schreiber D; Gruss C; Freitag M; von Kobyletzki G; Kerscher M; Altmeyer P
Hautarzt; 1999 Feb; 50(2):131-5. PubMed ID: 10097957
[TBL] [Abstract][Full Text] [Related]
4. Radiation-induced morphoea treated with UVA-1 phototherapy.
Lim D; Johnston S; Novakovic L; Fearfield L
Clin Exp Dermatol; 2014 Jul; 39(5):612-5. PubMed ID: 24890985
[TBL] [Abstract][Full Text] [Related]
5. Medium-dose is more effective than low-dose ultraviolet A1 phototherapy for localized scleroderma as shown by 20-MHz ultrasound assessment.
Sator PG; Radakovic S; Schulmeister K; Hönigsmann H; Tanew A
J Am Acad Dermatol; 2009 May; 60(5):786-91. PubMed ID: 19211170
[TBL] [Abstract][Full Text] [Related]
6. Low-dose UVA phototherapy for treatment of localized scleroderma.
Kerscher M; Volkenandt M; Gruss C; Reuther T; von Kobyletzki G; Freitag M; Dirschka T; Altmeyer P
J Am Acad Dermatol; 1998 Jan; 38(1):21-6. PubMed ID: 9448200
[TBL] [Abstract][Full Text] [Related]
7. High-dose ultraviolet A1 (UVA1) phototherapy: does it work?
Krutmann J
Photodermatol Photoimmunol Photomed; 1997 Jun; 13(3):78-81. PubMed ID: 9372519
[No Abstract] [Full Text] [Related]
8. Biological effects of a new ultraviolet A
Arndt S; Lissner C; Unger P; Bäumler W; Berneburg M; Karrer S
Exp Dermatol; 2020 Dec; 29(12):1199-1208. PubMed ID: 32592187
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of medium-dose ultraviolet A1 phototherapy in localized scleroderma.
Su O; Onsun N; Onay HK; Erdemoglu Y; Ozkaya DB; Cebeci F; Somay A
Int J Dermatol; 2011 Aug; 50(8):1006-13. PubMed ID: 21781079
[TBL] [Abstract][Full Text] [Related]
10. High-dose UVA1 radiation therapy for localized scleroderma.
Su RC; Chong LY; Lo KK
J Am Acad Dermatol; 1998 Sep; 39(3):517-8. PubMed ID: 9738800
[No Abstract] [Full Text] [Related]
11. Ultraviolet A1 phototherapy for the treatment of localized scleroderma.
Furuhashi T; Torii K; Ikumi K; Kato H; Nishida E; Morita A
J Dermatol; 2020 Jul; 47(7):792-795. PubMed ID: 32383187
[TBL] [Abstract][Full Text] [Related]
12. Clinical, histological and high-frequency ultrasonographic evaluation (50 MHz) of morphoea treated with ultraviolet A1 phototherapy.
Arisi M; Lorenzi L; Incardona P; Fusano M; Zanca A; Rossi MT; Tomasi C; Calzavara-Pinton PG; Venturini M
Clin Exp Dermatol; 2019 Apr; 44(3):270-276. PubMed ID: 29974485
[TBL] [Abstract][Full Text] [Related]
13. Successful ultraviolet A1 phototherapy in the treatment of localized scleroderma: a retrospective and prospective study.
Andres C; Kollmar A; Mempel M; Hein R; Ring J; Eberlein B
Br J Dermatol; 2010 Feb; 162(2):445-7. PubMed ID: 19785603
[TBL] [Abstract][Full Text] [Related]
14. High-dose UVA1 radiation therapy for localized scleroderma.
Stege H; Berneburg M; Humke S; Klammer M; Grewe M; Grether-Beck S; Boedeker R; Diepgen T; Dierks K; Goerz G; Ruzicka T; Krutmann J
J Am Acad Dermatol; 1997 Jun; 36(6 Pt 1):938-44. PubMed ID: 9204059
[TBL] [Abstract][Full Text] [Related]
15. Ultraviolet A1 phototherapy decreases inhibitory SMAD7 gene expression in localized scleroderma.
Kreuter A; Hyun J; Skrygan M; Sommer A; Tomi NS; Breuckmann F; Altmeyer P; Gambichler T
Arch Dermatol Res; 2006 Nov; 298(6):265-72. PubMed ID: 17009056
[TBL] [Abstract][Full Text] [Related]
16. Recurrence of morphea after successful ultraviolet A1 phototherapy: A cohort study.
Vasquez R; Jabbar A; Khan F; Buethe D; Ahn C; Jacobe H
J Am Acad Dermatol; 2014 Mar; 70(3):481-8. PubMed ID: 24365168
[TBL] [Abstract][Full Text] [Related]
17. Treatment regimens, protocols, dosage, and indications for UVA1 phototherapy: facts and controversies.
Gambichler T; Terras S; Kreuter A
Clin Dermatol; 2013; 31(4):438-454. PubMed ID: 23806161
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of medium-dose UVA1 phototherapy in localized scleroderma with the cutometer and fast Fourier transform method.
de Rie MA; Enomoto DN; de Vries HJ; Bos JD
Dermatology; 2003; 207(3):298-301. PubMed ID: 14571073
[TBL] [Abstract][Full Text] [Related]
19. Ultraviolet A1-induced downregulation of human beta-defensins and interleukin-6 and interleukin-8 correlates with clinical improvement in localized scleroderma.
Kreuter A; Hyun J; Skrygan M; Sommer A; Bastian A; Altmeyer P; Gambichler T
Br J Dermatol; 2006 Sep; 155(3):600-7. PubMed ID: 16911288
[TBL] [Abstract][Full Text] [Related]
20. The safety and efficacy of light emitting diodes-based ultraviolet A1 phototherapy in bleomycin-induced scleroderma in mice.
Karpec D; Rudys R; Leonaviciene L; Mackiewicz Z; Bradunaite R; Kirdaite G; Venalis A
Adv Med Sci; 2018 Mar; 63(1):152-159. PubMed ID: 29120857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
